Similac, Pediasure Drive Abbott’s Ross Sales In 2007
This article was originally published in The Tan Sheet
Executive Summary
Similac, PediaSure and the launch of NutriPals bars and shakes drove sales by Abbott Laboratories' Ross U.S. Nutritionals unit up 3 percent to $624 million in its fourth quarter, according to Abbott President and COO Rick Gonzalez
You may also be interested in...
Abbott Credits International Markets For Present, Future Growth
International sales of Abbott's nutritional products increased 15.6 percent to $515 million in its latest quarter as a result of "focused promotional efforts and sales force activities," the firm said Oct. 17
Abbott’s Expectation Accurate: U.S. Nutritional Product Sales Down
International sales for Abbott Laboratories' nutritional products increased 13.4 percent in its fiscal 2007 first quarter, but the firm's expectation of a decrease in its U.S. nutritional sales proved accurate
Sales & Earnings In Brief
J&J: The launch of reformulated Tylenol upper respiratory products by McNeil Consumer & Specialty Pharmaceuticals contributed in part to a 5.9% increase in U.S. consumer sales to $1.13 bil. during the third quarter when compared to the prior-year period, the firm states Oct. 17. Worldwide Consumer sales were $2.5 bil., an increase of 10.1% over the prior year. Net income for the quarter rose to $2.76 bil. from $2.54 bil. in the year-ago period. J&J expects to finalize the acquisition of Pfizer's consumer unit in the latter half of December, CFO Bob Derretta said during a same-day call with analysts. J&J announced the purchase of Pfizer's consumer division in June (1"The Tan Sheet" July 3, 2006, p. 3)...